Evidence map›Paper›PMID 37251929›Full record

ArticleFrontiers in oncology2023

Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer.

Maroun Bou Zerdan, Prashanth Ashok Kumar, Dulce M Barrios, Alanna Glidden, Dayana Nasr, Stephanie Niforatos, Ghanshyam Ghelani, Jennifer Leibovitch, Sandy Nasr, Binod Kc and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Metabolic syndrome and immune-related adverse events.Cancer immunology, immunotherapy : CII · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Maroun Bou ZerdanDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Prashanth Ashok KumarDivision of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Dulce M BarriosDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Alanna GliddenDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Dayana NasrDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Stephanie NiforatosDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Ghanshyam GhelaniDivision of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Jennifer LeibovitchDivision of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Sandy NasrDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Binod KcDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Mulham OmbadaDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Farzam KhokharDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Bhavya PoudyalDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Jenish BhandariDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Myera ShahnawazDepartment of Medicine, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Stephen GrazianoDivision of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
Seah H LimDivision of Hematology and Oncology, State University of New York Upstate Medical University, Syracuse, New York, NY, United States.
SUNY Upstate Medical University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Many co-existing medical conditions may affect the outcome in patients treated with immune checkpoint inhibitors for advanced cancer. There is currently not any information on whether metabolic syndrome (MetS) impacts the clinical outcome in patients treated with immune checkpoint inhibitors (ICIs) for advanced non-small cell line cancer (NSCLC). Methods: We carried out a single-center retrospective cohort study to determine the effects of MetS on first-line ICI therapy in patients with NSCLC. Results: One hundred and eighteen consecutive adult patients who received first-line therapy with ICIs and had adequate medical record information for the determination of MetS status and clinical outcomes were included in the study. Twenty-one patients had MetS and 97 did not. There was no significant difference between the two groups in age, gender, smoking history, ECOG performance status, tumor histologic types, pre-therapy use of broad-spectrum antimicrobials, PD-L1 expression, pre-treatment neutrophil:lymphocyte ratio, or proportions of patients who received ICI monotherapy or chemoimmunotherapy. With a median follow-up of 9 months (range 0.5-67), MetS patients enjoyed significantly longer overall survival (HR 0.54, 95% CI: 0.31-0.92) ( Conclusions: Our results suggest that MetS is an independent predictor of treatment outcome in patients who received first-line ICI monotherapy for NSCLC.

Indexed as

chemoimmunotherapyimmune checkpoint inhibitorsmetabolic syndromenon-small cell lung cancertreatment outcome

Identifiers

PMID37251929
PMCPMC10213668
OpenAlexW4376279566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.